FDA Inspection 1070932 — David Dingli
The FDA completed an inspection of David Dingli on Oct 12, 2018 in Rochester, MN. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 12, 2018
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Rochester, MN (United States)
Additional Details
Clinical Investigator (CI)